After graduating from the Law Center in 1987, Professor Girard joined the law firm of Silverstein & Mullens, where she practiced tax law. In 1989, she joined the law firm of Patton Boggs, where she practiced food and drug law, specializing in the representation of cosmetic, pharmaceutical and biotech companies in FDA-related proceedings and other regulatory and policy matters. In 1994, Professor Girard moved to Hogan & Hartson, where she expanded her representation to include the blood and tissue industries.
Scholarship
Contributions to Law Reviews and Other Scholarly Journals
Vicki W. Girard,
Punishing Pharmaceutical Companies for Unlawful Promotion of Approved Drugs: Why the False Claims Act Is the Wrong Rx, 12 J. Health Care L. & Pol'y 119-158 (2009). [
Gtown Law] [
HEIN] [
W] [
L] [
SSRN]
Selected Contributions to Other Publications
Vicki W. Girard,
Reducing Unlawful Prescription Drug Promotion: Is the Public Health Being Served by an Enforcement Approach that Focuses on Punishment?, Food & Drug Pol'y F., Oct. 24, 2012, at 1-18. [
Gtown Law] [
SSRN]
Book Chapters & Collected Works
Vicki W. Girard, Robert P. Brady & Molly S. Newberry,
The Food and Drug Administration's Statutory and Regulatory Authority to Regulate Human Pluripotent Stem Cells, in 2 Ethical Issues in Human Stem Cell Research B-1 to B-12 (Rockville, Md.: National Bioethics Advisory Commission 2000). [
WWW] [
BOOK]
